Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Toshner
Less than a year to develop a COVID vaccine – here’s why you shouldn’t be alarmed
Photo by Daniel Schludi on Unsplash Mark Toshner, University of Cambridge I’m a clinical trials geek. I keep hearing people talk about the seven to ten years it takes to make a vaccine and how dangerous speeding this up might be. The word that keeps popping up is “rushed”, and it is making the average person nervous about vaccine safety. So, as a clinical trials doctor, I am going to tell you what I do for most of those ten years – and it is not very much. I’m not lazy.
Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension
|
Editor’s summary Abstract INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS Acknowledgments Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations View Options References Figures Tables Media Share Editor’s summary Pulmonary arterial hypertension (PAH) does not have many treatment options, and pulmonary biopsies are unsafe in these patients, so biomarkers of target engagement are needed for clinical trials.
By Olha Melnyk, Rowena Jones, Leslie Wagner, Eckart De Bie, Nina Deliu, Anthony Y. K. C. Ng, Benjamin J. Dunmore, Stefan Gräf, Christophe Guignabert, Marc Humbert, Laurent Savale, Athénaïs Boucly, Joseph A. Newman, Gary Polwarth, Paul D Upton, Allan Lawrie, Christopher Rhodes, Martin Wilkins, Anna R. Hemnes, Sofía Villar Verified, James West, Mark Toshner, Nicholas W. Morrell, Sarah K. Binmahfooz, Alexander M.K. Rothman
|
Science Magazine
Verified
Digital Data Collection Reduces Terminal Digit Bias in Haemodynamic and Physical Activity Measures in Pulmonary Arterial Hypertension
The authors have declared no competing interest. NCT04078243 MRC Exp Med MR/W026279/1 EPSRC EP/Z531297/1 I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
What to do when pulmonary arterial hypertension screening suggests neither fish nor fowl? The DOLPHIN-GENESIS study
Footnotes Conflict of interest: M. Toshner declares relationships with Janssen Pharmaceuticals Inc., Merck Sharp & Dohme UK Ltd, and Apollo Therapeutics that include consulting and/or advisory work. E.M.D.D. De Bie has no potential conflicts of interest to disclose. Support statement: M. Toshner is supported by the NIHR Cambridge Biomedical Research Centre. E.M.D.D. De Bie is supported by the Gates Cambridge Trust (Gates grant number OPP1144).
Physician associates: A solution for health care staff shortages or a colonial throwback?
Before the COVID pandemic, the global health workforce needed as many as 6.4 million more medical doctors, and the gap between demand for health workers and supply is growing. As you might expect, the shortage is most acutely felt in low- and middle-income countries. The latest World Health Organization (WHO) statistics show that 30 countries have fewer than two doctors for every 10,000 people. Twenty-seven of these are in Africa, while the remaining three are Pacific Island nations.
Physician associates: a solution for healthcare staff shortages or a colonial throwback?
Before the COVID pandemic, the global health workforce needed as many as 6.4 million more medical doctors, and the gap between demand for health workers and supply is growing. As you might expect, the shortage is most acutely felt in low- and middle-income countries. The latest World Health Organization (WHO) statistics show that 30 countries have fewer than two doctors for every 10,000 people. Twenty-seven of these are in Africa, while the remaining three are Pacific Island nations.
Sotatercept in pulmonary arterial hypertension: something different or more of the same? - Nature Cardiovascular Research
Sotatercept is the first successful therapy to make it through phase 3 to regulatory submission in pulmonary arterial hypertension that is not proposed to work via vasodilatory mechanisms. The phase 3 STELLAR study of sotatercept treatment challenges established thinking on pulmonary vascular remodeling and offers patients hope for a step change in outcomes.
Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021
CTEPH is caused by obstruction of pulmonary arteries by chronic organised fibrotic clots in addition to varying degrees of microvasculopathy contributing to PH. It is defined by the combination of pre-capillary PH, mismatched perfusion defects on V′/Q′ lung scan and specific signs of chronic clots on CTPA or CPA after at least 3 months of therapeutic anticoagulation. CTEPD, which includes CTEPH, can also be observed without PH. PEA is the treatment of choice for CTEPH.
Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial.
Abstract Background The role of thromboprophylaxis in the post-acute phase of COVID-19 is uncertain due to conflicting results from randomised controlled trials and observational studies. We aimed to determine the effectiveness of post-hospital apixaban in reducing the rate of death and hospital readmission of hospitalised adults with COVID-19.
With no treatment in sight for long Covid, some patients are opting for ‘blood washing’
A recent investigation published by the British Medical Journal revealed that long Covid patients are travelling abroad to seek expensive “blood washing” treatment. This experimental treatment – the medical name for which is apheresis – involves taking blood from the body and “filtering” it. Essentially, when blood is spun quickly in a centrifuge, it separates into layers. You can then either filter out specific components or remove some layers and replace these with more desirable fluids.
Long COVID: Still no treatment options
A recent investigation published by the British Medical Journal revealed that long COVID patients are travelling abroad to seek expensive "blood washing" treatment. This experimental treatment – the medical name for which is apheresis – involves taking blood from the body and "filtering" it. Essentially, when blood is spun quickly in a centrifuge, it separates into layers. You can then either filter out specific components or remove some layers and replace these with more desirable fluids.
with no treatment options, it's little wonder people are seeking unproven therapies like 'blood washing'
A recent investigation published by the British Medical Journal revealed that long COVID patients are travelling abroad to seek expensive “blood washing” treatment. This experimental treatment – the medical name for which is apheresis – involves taking blood from the body and “filtering” it. Essentially, when blood is spun quickly in a centrifuge, it separates into layers. You can then either filter out specific components or remove some layers and replace these with more desirable fluids.
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
Mark Toshner, Colin Church, Lars Harbaum, Christopher Rhodes, Sofia S. Villar Moreschi, James Liley, Rowena Jones, Amit Arora, Ken Batai, Ankit A. Desai, John G. Coghlan, J. Simon R. Gibbs, Dee Gor, Stefan Gräf, Louise Harlow, Jules Hernandez-Sanchez, Luke S. Howard, Marc Humbert, Jason Karnes, David G. Kiely, Rick Kittles, Emily Knightbridge, Brian Lam, Katie A. Lutz, William C. Nichols, Michael W. Pauciulo, Joanna Pepke-Zaba, Jay Suntharalingam, Florent Soubrier, Richard C. Trembath, Tae-Hwi L.
Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH
Mark Toshner, Colin Church, Lars Harbaum, Christopher Rhodes, Sofia S. Villar Moreschi, James Liley, Rowena Jones, Amit Arora, Ken Batai, Ankit A. Desai, John G. Coghlan, J. Simon R. Gibbs, Dee Gor, Stefan Gräf, Louise Harlow, Jules Hernandez-Sanchez, Luke S. Howard, Marc Humbert, Jason Karnes, David G. Kiely, Rick Kittles, Emily Knightbridge, Brian Lam, Katie A. Lutz, William C. Nichols, Michael W. Pauciulo, Joanna Pepke-Zaba, Jay Suntharalingam, Florent Soubrier, Richard C. Trembath, Tae-Hwi L.
Long COVID: with one in three patients back in hospital after three months, where are the treatments?
The pace of acute therapy and vaccine development for COVID have been dizzying. But even as we hope a route to bringing the pandemic under control is within sight, we’re now facing the possibility of another urgent public health emergency thanks to what’s known as long COVID, a group of symptoms that last long after the initial infection. With such a potential crisis looming, it is reasonable to ask what we are doing about it, and why treatments don’t appear to be forthcoming.
Is Britain heading for another winter lockdown?
What do you think the chances are of another national lockdown before the year is out? Are you glass half empty, glass half full, or do you question if there is really a glass at all? I think a lot of people are looking at the same Covid data right now and coming to wildly different conclusions. The pandemic has been characterised by these moments. The days and weeks pass until reality can no longer be ignored, at which point it is usually too late to prevent catastrophe, but in time to mitigate it.
Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom
Background Clinical trials are the cornerstone of modern medicine, providing scientific evidence to treat patients safely and effectively. In the context of novel drugs or vaccines, preclinical data generated in the laboratory and in animal models are used to inform and design clinical trials in humans.
COVID vaccines: how to make sense of reports on their effectiveness
As a middling but competent clinician-scientist, I feel desperately sorry for the general public trying to make head or tail of some of the scientific discussions on the pandemic right now. Science is being done, disseminated, argued about – sometimes peer-reviewed if we are lucky – and then immediately rewritten days later. Even with some experience, it’s hard to keep up. Data and reports come thick and fast, with little time to assess what they really mean.
We could all pay the price for the EU’s foolish vaccine nationalism
I’m a card carrying, Europe-loving, wishy-washy centre-left liberal. It therefore pains me to point this out: the EU in general, Ursula von der Leyen specifically, and some of the prominent European leaders such as Emmanuel Macron are getting policy and messaging on vaccines badly wrong. They need to urgently ditch the peacock displays of tribal politics.
Szczepionka na Covid-19 powstała w niecały rok. Oto dlaczego to bardzo dobra wiadomość
Badanie szczepionek nie trwa dziesięć lat dlatego, że tak jest bezpiecznie. To ciężkie lata walki z obojętnością, nakazami rynku, losem i biurokracją – pisze Mark Toshner, dyrektor ds. praktycznego zastosowania badań biomedycznych na University of Cambridge. Mam obsesję na punkcie badań klinicznych. Ludzie często powtarzają, że potrzeba siedmiu do dziesięciu lat, aby stworzyć szczepionkę i jak niebezpieczne może być przyspieszanie tego procesu. Słowo, którego wciąż się nadużywa, to „pośpiech”.
UK citizens get less legal protection for COVID jabs than other vaccines - and that could undermine confidence
Of all the concerns the public has about vaccine safety, there is one that has us stumped for a straightforward answer: “If the vaccines are safe, why is the government protecting itself, health professionals and companies from vaccine compensation?” In fact, the UK government has passed regulations reducing legal protection for anyone injured by a COVID-19 vaccine approved for emergency use.
Don’t panic about the COVID vaccine allergy risk
Europe World In the coming weeks and months, we are going to suffer from the most severe form of what is known as ‘observer bias’ In the coming weeks, you are inevitably going to see a slew of stories in the media about side effects from the licensed vaccines. The first one is already with us here in the UK. Two healthcare staff — who both have a history of allergic reactions — have reportedly had adverse reactions to the Pfizer vaccine.
'Less than a year to develop a COVID vaccine - here’s why you shouldn’t be alarmed'
The word that keeps popping up is “rushed”. I’m a clinical trials geek. I keep hearing people talk about the seven to ten years it takes to make a vaccine and how dangerous speeding this up might be. The word that keeps popping up is “rushed”, and it is making the average person nervous about vaccine safety. So, as a clinical trials doctor, I am going to tell you what I do for most of those ten years – and it is not very much. I’m not lazy.
The dangers of COVID-19 far outweigh the risks of a vaccine
For all the good news that has emerged about COVID-19 vaccines in recent weeks, it is clear that we are not doing a particularly good job addressing people’s reasonable concerns about vaccine safety. Before we go on though, it is important for you to know who I am, and who I am not. I am a minor academic in a decent university in England.
Less than a year to develop a COVID vaccine – here’s why you shouldn’t be alarmed - Alliance for Science
I’m a clinical trials geek. I keep hearing people talk about the seven to 10 years it takes to make a vaccine and how dangerous speeding this up might be. The word that keeps popping up is “rushed” and it is making the average person nervous about vaccine safety. So, as a clinical trials doctor, I am going to tell you what I do for most of those 10 years — and it is not very much. I’m not lazy.
COVID-19: un vaccin développé en moins d’un an? Voici pourquoi il ne faut pas s’inquiéter
BioNTech/EPA Je connais très bien l’univers des essais cliniques et j’entends sans cesse que fabriquer un vaccin prend de sept à dix ans et qu’il est dangereux d’accélérer le processus. Le commentaire qui revient souvent est que les essais sont «précipités», ce qui peut créer des inquiétudes parmi la population quant à la sécurité du vaccin.
Développer un vaccin contre la Covid en moins d’un an ? Voici pourquoi il n’y a pas lieu de s’inquiéter
Je connais très bien l’univers des essais cliniques et j’entends sans cesse que fabriquer un vaccin prend de sept à dix ans et qu’il est dangereux d’accélérer le processus. Le commentaire qui revient souvent est que les essais sont « précipités », ce qui peut créer des inquiétudes parmi la population quant à la sécurité du vaccin.
Less Than a Yr to Make COVID Vaccine: Why You Shouldn’t Be Alarmed
I’m not lazy. I submit grants, have them rejected, resubmit them, wait for review, resubmit them somewhere else, sometimes in a loop of doom. When I am lucky enough to get trials funded, I then spend months on submitting to ethics boards.
Less than a year to develop a COVID vaccine – here's why you shouldn't be alarmed Original
I’m a clinical trials geek. I keep hearing people talk about the seven to ten years it takes to make a vaccine and how dangerous speeding this up might be. The word that keeps popping up is “rushed”, and it is making the average person nervous about vaccine safety. So, as a clinical trials doctor, I am going to tell you what I do for most of those ten years – and it is not very much. I’m not lazy.
Thread by @mark_toshner on Thread Reader App
More on vaccines. I'm going to get boring and geeky on this (no apologies) on the 10 year thing. Vaccines "normally take 10 years". This is being use as a reason to be fearful (ie rushed job). I'm a clinical trials doc. I can tell you most of that time is spent doing...1/n .... nothing.
IL-6 in pulmonary hypertension: why novel is not always best
Mark Toshner, Alex Rothman European Respiratory Journal 2020 55: 2000314; DOI: 10.1183/13993003.00314-2020 Abstract Previous preclinical data on IL-6 validated in a large multicentre biobank study. IL-6 is associated with mortality and levels vary related to underlying aetiology. This has relevance to experimental medicine attempts to translate immunomodulatory therapy. https://bit.ly/2WTFUMQ In this issue of the European Respiratory Journal, Simpson et al.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack